Catabasis Pharma (CATB): Preview of Edasalonexent Proof-Of-Concept Study - Wedbush
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wedbush analyst, Heather Behanna, reiterated her Outperform rating on shares of Catabasis Pharma (NASDAQ: CATB) and her price target of $17 representing more than a 4x return on investment. The MoveDMD proof-of-concept study enrollment is complete and the analyst expects data in the first six weeks of 1Q17.
The analyst believes the science behind Catabasis’s NF-kB inhibitor, edasalonexent (CAT-1004), is sound and recent data from the World Muscle Society (WMS) suggests the compound is knocking down NF-kB in DMD boys. The analyst sees a compelling risk/reward for edasalonexent, with a best case scenario of a significant benefit (as measured by MR) at three months.
Boys will continue to be studied through a year to see functional changes and the analyst believes the six-month data can drive pivotal trial design and allow a greater time window for the benefit to be observed.
Shares of Catabasis closed at $4.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Downgrades Kroger (KR) to Hold
- Jefferies Cuts Price Target on PG&E Corp. (PCG) to $65 Following Rate Case Decision
- Jefferies Raises Price Target on US Physical Therapy (USPH) to $63 Following 12-Clinic Acquisition
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!